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Abstract
Objective: The objective of this selective EBM review is to determine whether or not anti-PD1/PD-L1 monoclonal antibodies are effective in prolonging overall survival in patients with
advanced non-small cell lung cancer (NSCLC).
Study Design: A systematic review and data analysis of three randomized control trials (RCTs)
published after 2010. The studies were located in English written peer reviewed journals.
Data sources: Three RCTs, which evaluated the efficacy of anti-PD-1/PD-L1 monoclonal
antibodies, including nivolumab and pembrolizumab, as first and second or consecutive line
therapy in patients with advanced NSCLC compared to cytotoxic agents. The studies utilized
were found in EBSCO host and PubMed.
Outcomes Measured: The primary endpoint of the studies was overall survival measured by
quantifying survival rates at 6, 12, or 18 months.
Results: All three RCTs (Borghaei 2015, Brahmer 2015, and Reck 2016) showed that anti PD-1
monoclonal antibodies are effective in prolonging overall survival in patients with advanced
NSCLC whose tumors expressed PD-L1 (p=.002, p<.001, and p=.005 respectively). All three
studies proved that immunomodulating agents caused an increase in overall survival rates
compared to those treated with chemotherapeutic agents as first and second or consecutive line
therapy. Additionally, median overall survival time in months was significantly longer in patients
who were treated with immunomodulating agents compared to cytotoxic agents.
Conclusion: Based on the data analyzed from the studies represented throughout this systematic
review, anti PD-1 monoclonal antibodies are effective in prolonging overall survival in patients
with advanced NSCLC. It is unclear whether or not anti PD-L1 monoclonal antibodies are
effective in prolonging overall survival in the same populations of NSCLC patients due to a lack
of viable study selection found during the search process. All study conclusions were based on
malignancies which expressed PD-L1 in their tumors.
Keywords: NSCLC; PD1/PD-L1 Monoclonal Antibodies; Nivolumab; Pembrolizumab.
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Introduction
Lung cancer is a devastating disease that often doesn’t present itself until its later stages.
Once symptomatic, a patient may present with constitutional manifestations such as fever, night
sweats, fatigue, and weight loss. Symptoms related to the local invasion of the cancer include
cough, hemoptysis, shortness of breath, back pain, and chest pain. A diagnosis of lung cancer can
be made when pathology confirms malignancy of tumors originating in the lung or bronchus.
The disease can then be further broken down into non-small cell and small cell, or NSCLC and
SCLC respectively. NSCLC is much more common, accounting for approximately 80% of all
lung cancer cases and comprises adenocarcinoma, squamous cell carcinoma, large cell
carcinoma, and other less common malignant subtypes.1 Of the individuals who are diagnosed
with NSCLC, over 50% are diagnosed with advanced disease, which generally includes stage
IIIb and IV.1 This paper evaluates three randomized control trials (RCT’s) comparing the
effectiveness of anti-PD-1/PD-L1 monoclonal antibodies on prolonging overall survival in
patients with advanced non-small cell lung cancer.
As of 2018, lung cancer is the most common cancer diagnosed in males and the third
most common cancer diagnosed in females.2 In addition to its prevalence, lung cancer is the most
common cause of cancer related deaths in the United States.3 For NSCLC, these statistics are due
to two very critical diagnostic tools. First, Patients with NSCLC are often asymptomatic until the
disease has advanced to terminal stages.3 Second, there is a lack of standardized screenings for at
risk populations.3 As a result, it is imperative for health care providers to recognize risk factors
and educate the patient on the severity of lung cancer to help prevent and detect lung cancer
during earlier stages.
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Malignancies originating in the lung and bronchus are the third costliest cancers in the
United States.1 In 2011, the total healthcare costs over one year for lung cancer diagnosis and
treatment was estimated to be $125,849 per person.4 Although necessary, the increased cost of
lung cancer is due in part to comprehensive treatment that requires a complete healthcare team to
appropriately manage the patient’s physical, mental, and emotional health throughout the disease
course. Specifically, It is estimated that there will be 2 inpatient hospital admissions, 9
cumulative inpatient care days, and 70 outpatient care visits during a one year period in a patient
with NSCLC.4 Additionally, lung cancer risk increases with an individual’s age and older
individuals with NSCLC represent a particularly expensive sub group of the overall lung cancer
population due to comorbidities, disease burden, and lower overall performance.5 The cost
analyses documented for populations diagnosed with lung cancer demonstrate a significant
burden for patients and families.
Preventing lung cancer is the best way to minimize insurance and out-of-pocket costs due
to disease treatment. Prevention begins with identifying the most important risk factors and
modifying the patient’s lifestyle to reduce the likelihood of cancer development. Smoking is the
most important known risk factor for lung cancer and accounts for nearly 90% of all diagnoses.6
Other risk factors for the development of NSCLC include poor diet, genetic susceptibility, and
occupational exposures such as asbestos.6 When risk factors are present, it is uncertain if
screening should be implemented. The current screening offered as a USPSTF Grade B is an
annual low dose CT scan for adults 55-80 years old who have a 30 year or more pack-year
history, but there is controversy surrounding when it should be offered.7 As an example, it is
uncertain if higher risk populations, such as those with chronic bronchitis and emphysema,
should be screened earlier or at more frequent intervals.7
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Individuals who are diagnosed with NSCLC will endure varying degrees of treatment
based on the staging and subtype of their cancer. In general, surgical removal of tumor(s) with or
without regional lymph node resection is considered first line in patients with stage I-IIIa
NSCLC.8 Cancers with more advanced disease, such as in stage IIIb-IV, indicate chemotherapy
as first line therapy. For advanced NSCLC with no known tumor-specific mutations,
administration of platinum based chemotherapy “doublets” such as cisplatin and carboplatin is
warranted.8 Conversely, advanced NSCLC patients whose tumors express EGFR mutations are
advised to begin treatment with EGFR-TKI’s.9
Second line treatment for advanced NSCLC is limited and is dependent on the patient’s
disease progression after first line treatment fails.10 Docetaxel is the current recommended
second line treatment method, but has not been able to prove superiority to other current second
line therapies.10 Programmed death 1/L1 (PD-1/PD-L1) receptors are immunomodulating agents
that may offer superiority to the current first and second or third line treatment by prolonging
survival in advanced NSCLC patients whose tumors express PD-1/PD-L1. The benefit in these
medications is having more personalized treatment for diseases that involve the programmed cell
death 1/L1 pathway. The purpose of the medications are to bind PD-1/PD-L1 receptors on B and
T cells in the body and form an antibody complex.11 This prevents any tumor cells that express
PD-1/PD-L1 from binding at those same sites on B and T cells. Without tumor cell binding on B
and T cells, the immune system will be able to “restore antitumor immunity”.10 PD-1/PD-L1
monoclonal antibodies such as nivolumab and pembrolizumab, may be more effective at
prolonging overall survival than the current cytotoxic therapies recommended for first and
second or consecutive line treatment.
Objective
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The objective of this selective EBM review is to determine whether or not anti PD-1/PDL1 monoclonal antibodies are effective in prolonging overall survival in patients with advanced
non-small cell lung cancer (NSCLC).
Methods
This systematic review evaluates three randomized control trials (RCTs), which were
selected after meeting specific criteria. The population of the review included men and women
18 years or older with a confirmed diagnosis of advanced NSCLC and whose tumors expressed
PD-1/PD-L1. “Advanced NSCLC” can be defined as stages IIIb or IV. The interventions
included treatment with anti PD-1/PD-L1 monoclonal antibodies such as nivolumab and
pembrolizumab, in variable doses. There were two comparison groups allowed in the review.
The first comparison was to patients who have NOT received any treatment for their metastatic
disease and the second comparison was to patients who HAVE received prior treatment that has
failed/stopped. The primary outcome measured was overall survival rate over time, which
generally occurred at 6, 12, or 18 months.
The articles selected for this systematic review were obtained through EBSCO host and
PubMed. They are English written, peer reviewed articles and were chosen based on their
relevance to the research topic and whether or not the outcome was patient oriented. Additional
inclusion criteria for the selection of the studies were: studies published after 2010, tumors
expressing programmed death ligand, and primary outcomes measured by overall survival rate.
Patients under the age of 18 and patients diagnosed with SCLC were among exclusion criteria.
Keywords used during the search of the articles included NSCLC, PD1/PD-L1 monoclonal
antibodies, nivolumab and pembrolizumab. A statistical summary of data was reported as
p-value, RBI, ABI, and NNT. Confidence intervals were also included to demonstrate the
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accuracy of the results. Demographics and characteristics of individuals included in the study are
reported below (see table 1).
Table 1 - Demographics & Characteristics of Included Studies
Study

Type

# of
Pts

Borghaei
(2015)

RCT

582

Avg.
Age in
yrs
62

Brahmer
(2015)

RCT

272

63

Reck
(2016)

RCT

355

65

Inclusion Criteria

Exclusion Criteria

W
/D

Intervention

Patients with: stage IIIb,
IV or recurrent NonSquamous NSCLC who
received a previous dose
of platinum-based
doublet chemotherapy
and either radiation or
surgical tumor resection.
Patients had to be over
18 years old, have an
ECOG score of 0 or 1,
and have adequate organ
function.
Patients with: stage IIIb,
IV or recurrent
Squamous NSCLC who
received a previous dose
of platinum-based
doublet chemotherapy
and either radiation or
surgical tumor resection.
Patients had to be over
18 years old, and have an
ECOG score of 0 or 1.

Patients with:
autoimmune
disease,
symptomatic
interstitial lung
disease, systemic
immunosuppression,
prior treatment with
immune-stimulatory
antitumor agents,
and prior use of
docetaxel.

22

Use of
Nivolumab at
a dose of 3
mg/kg every
2 weeks

Patients with:
autoimmune
disease,
symptomatic
interstitial lung
disease, systemic
immunosuppression,
prior treatment with
immune-stimulatory
antitumor agents,
and prior use of
docetaxel.
Patients receiving
immunosuppressive
treatment such as
glucocorticoids,
with untreated brain
metastatic lesions,
active autoimmune
disease, or history of
interstitial lung
disease.

12

Use of
Nivolumab at
a dose of 3
mg/kg every
2 weeks

1

Use of
Pembrolizumab given via
IV at a dose
of 200 mg
every 3
weeks for 35
cycles

Patients with stage IV
NSCLC who were at
least 18 years old, had no
known ALK or EGFR
mutations, and had an
ECOG score of 0 or 1.
Patients must not have
received any prior
systemic therapy for
metastatic disease.

Outcomes
In the studies selected for this systematic review, the primary outcome was overall
survival of advanced NSCLC patients treated with PD-1/PD-L1 monoclonal antibodies as a first
and second or consecutive line therapy. Borghaei et al. and Brahmer et al. measured outcomes by
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assessing median overall survival time in months, 1 year overall survival rate, 18 month overall
survival rate, and death hazard ratio10,12 Reck et al. measured outcomes by assessing median
overall survival time in months, overall survival rate at 6 months, and hazard death rate.13
Overall survival was estimated via the Kaplan-Meier method. Response rate and progression free
survival were measured as secondary endpoints, but are not being evaluated as they are outside
of the scope of this systematic review. Symptomatic scales such as the Lung Cancer Symptom
Scale and the European Quality of Life-5 Dimension Questionnaire were evaluated as part of
progression free survival and will not be included in this review.
Results
In a study conducted by Borghaei et al., 582 patients with advanced non-squamous
NSCLC who were previously treated with a platinum-based doublet chemotherapy regimen were
randomized to receive nivolumab or docetaxel.10 292 of the 582 patients received nivolumab
while 290 of the 582 patients received docetaxel. No crossover was indicated for patients to
switch from docetaxel to nivolumab or vice versa.
The median overall survival in patients who received nivolumab as a second line therapy
was 12.2 months (95% confidence interval (CI), 9.7 to 15.0), and the median overall survival in
patients who received docetaxel as a second line therapy was 9.4 months (95% CI, 8.1 to 10.7).10
The 1 year overall survival rate was 51% (95% CI, 45 to 56) for individuals who received
nivolumab and 39% (95% CI, 33 to 45) for individuals who received docetaxel.10 An additional
follow-up conducted at 18 months showed that overall survival rates declined to 39% (95% CI,
34 to 45) in the nivolumab group versus 23% (95% CI, 19 to 28) in the docetaxel group.10 The
hazard ratio for death was calculated to be .73 (96% CI, 0.59 to 0.89, p=.002).10 Utilizing data
from the 1 year survival rate, the numbers needed to treat (NNT) was 9 (see Table 2). This
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indicates that for every 9 people treated with nivolumab, 1 person will live longer than if they
had taken docetaxel. Overall, patients with advanced non-squamous NSCLC who received
nivolumab as a second or consecutive line therapy lived significantly longer compared to those
treated with docetaxel.
Table 2 – Efficacy of nivolumab as a second line therapy in prolonging overall survival in
patients with advanced NSCLC, measured by Borghaei 2015
Study

Relative Benefit
Increase (RBI)

Absolute Benefit
Increase (ABI)

Borghaei
(2015)

.307

.120

Numbers
Needed to
Treat (NNT)
9

Death Hazard
Ratio P-Value
.002

Death Hazard
Ratio Confidence
Interval (CI)
96% CI,
.59-.89

In a similar study conducted by Brahmer et al., 272 patients with advanced squamous
non-small cell lung cancer who were previously treated with a regimen containing platinumbased chemotherapy were randomized to receive nivolumab or docetaxel.12 137 of the 272
patients received nivolumab while 137 of the 272 patients received docetaxel. No crossover was
indicated during the study.
The median overall survival in patients who received nivolumab as a second line therapy
was 9.2 months (95% CI, 7.3 to13.3), and the median overall survival in patients who received
docetaxel as a second line therapy was 6.0 months (95% CI, 5.1 to 7.3).12 The 1 year overall
survival rate was 42% (95% CI, 34 to 50) for individuals who received nivolumab and 24%
((95% CI, 17 to 31) for individuals who received docetaxel.12 The hazard ratio for death was
calculated to be .59 (95% CI, 0.44 to 0.79, P<0.001).12 Utilizing data from the 1 year survival
rate, the numbers needed to treat (NNT) was 6 (see Table 3). This indicates that for every 6
people treated with nivolumab, 1 person will live longer than if they had taken docetaxel.
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Therefore, patients with advanced squamous NSCLC who received nivolumab lived significantly
longer compared to those treated with docetaxel.
Table 3 – Efficacy of nivolumab as a second line therapy in prolonging overall survival in
patients with advanced NSCLC, measured by Brahmer 2015
Study

Relative Benefit
Increase (RBI)

Absolute Benefit
Increase (ABI)

Brahmer
(2015)

.750

.180

Numbers
Needed to
Treat (NNT)
6

Death Hazard
Ratio P-Value
<.001

Death Hazard
Ratio Confidence
Interval (CI)
95% CI,
.44-.79

Lastly, a study by Reck et al. was conducted to test the efficacy of pembrolizumab
against advanced NSCLC. The study included 305 patients who had not been previously treated
with any form of chemotherapy or radiation. 154 patients were treated with pembrolizumab and
151 patient were treated with chemotherapy.13 The most common chemotherapeutic combination
was carboplatin and pemetrexed, which was given to 67 out of the 151 patients. Crossover was
allowed during this study if disease had progressed beyond an acceptable margin.13 In total, 66
people in the chemotherapy group crossed over to the pembrolizumab group.
The 6 month overall survival rate in patients who received pembrolizumab as a first line
therapy was 80.2% (95% CI, 72.9 to 85.7) and the 6 month overall survival rate in patients who
received chemotherapy as a first line therapy was 72.4% (95% CI, 64.5 to 78.9).13 The hazard
ratio for death was calculated to be .60 (95% CI, 0.41 to 0.89; P= 0.005).13 Utilizing data from
the 1 year survival rate, the numbers needed to treat (NNT) was 13 (see Table 4). This indicates
that for every 13 people treated with pembrolizumab, 1 person will live longer than if they had
taken chemotherapy. Therefore, patients with advanced NSCLC who received pembrolizumab as
first line therapy lived significantly longer compared to those treated with chemotherapy alone.
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Table 4 – Efficacy of pembrolizumab as first line therapy in prolonging overall survival in
patients with advanced NSCLC, measured by Reck 2016
Study

Relative Benefit
Increase (RBI)

Absolute Benefit
Increase (ABI)

Reck
(2016)

.108

.078

Numbers
Needed to
Treat (NNT)
13

Death Hazard
Ratio P-Value
.005

Death Hazard
Ratio Confidence
Interval (CI)
95% CI,
.41-.89

Discussion
Advanced non-small cell lung cancer is a terminal illness that typically weighs heavily on
a patient in all aspects of their lives. Treatment options often exclude surgical tumor resection
and focus solely on systemic cytotoxic agents that have limited efficacy. With advances in
funding and research, metastatic lung neoplasia may be treated by modifying the immune
response to the disease. The goal of this systematic review was to assess the efficacy of anti PD1/PD-L1 monoclonal antibodies in multiple stages of a patient’s treatment regimen, including as
first and second line therapies. While the data collected points towards immunomodulators being
effective in prolonging overall survival, several limitations and safety concerns have been
identified relating to the context of this paper.
As the two medications studied for effectiveness, nivolumab and pembrolizumab were
relatively safe medications offered compared to the current chemotherapeutic treatment options
available for advanced NSCLC. Borghaei et al. and Brahmer et al. both identified that there were
fewer adverse reactions with nivolumab compared to the chemotherapeutic agent, docetaxel.10,12
Both studies evaluating nivolumab also reported similar adverse effects. Borghaei et al.
documented that 16% of patients reported fatigue, 12% reported nausea, 10% reported decreased
appetite, and 10% reported asthenia with nivolumab.10 Less common adverse events included
rash, pruritis, erythema, diarrhea, hypothyroidism, increased liver function tests, and
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pneumonitis.10 Brahmer et al. identified similar frequent side effects of nivolumab, including
16% of patients reported fatigue, 11% reported decreased appetite, and 10% reported asthenia.12
The safety profile of pembrolizumab was comparative to nivolumab, and showed that the most
frequent adverse effects were immune-mediated responses to the medication.13
One important aspect relating to the use of monoclonal antibodies in treatment for
advanced NSCLC is at what point the medications should be started. Through topic research, it
was very clear that anti PD-1/PD-L1 monoclonal antibodies were studied as consecutive-line
therapy in greater lengths. While Reck et al. focused on pembrolizumab as a first line agent for
lung metastasis, both of the nivolumab studies conducted by Borghaei et al. and Brahmer et al.
focused on therapy following a platinum-based doublet chemotherapy regimen.10,12,13 Efficacy
was proven in all studies, but more research should be conducted to evaluate patient survival at
several intervals following diagnosis, with and without prior and/or concurrent therapy.
A major limitation identified in the research of this evidence based medicine topic was
the lack of available studies showing the efficacy specifically for PD-L1 monoclonal antibodies.
Nivolumab and pembrolizumab are specifically known as PD-1 monoclonal antibodies, and
these two medications were the only immunomodulators evaluated in this paper. Three PD-L1
monoclonal antibodies that have been approved as immunomodulating agents, including
atezolizumab, avelumab, and durvalumab. These medications have not been evaluated in this
paper due to the lack of articles found during the selective search process. Nivolumab and
pembrolizumab have been FDA approved since 2014, allowing more time for research to be
conducted on their efficacy.10,12 Atezolizumab, avelumab, and durvalumab were approved in
2016, 2017, and 2017 respectively and thus have less research available on their efficacy.
Additionally, avelumab has not been approved yet for the treatment of advanced NSCLC.14 With
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more funding and time, a greater number of RCT’s, cohort studies, and other analyses will be
conducted across the entire PD-1/PD-L1 spectrum. With more studies available, a more
comprehensive answer to the EBM question can be established.
Conclusion
Anti PD-1 monoclonal antibodies are effective in prolonging overall survival in patients
with advanced NSCLC. Unfortunately, it is unclear whether or not anti PD-L1 monoclonal
antibodies have similar efficacy because there was very limited research evaluating medications
that fall within its class. Nivolumab and pembrolizumab, which are anti PD-1 monoclonal
antibodies, can be implemented in patients whose tumors express PD-L1 as first or consecutive
line therapy as they are generally considered safer and more effective to the current
recommended therapy. Atezolizumab, avelumab, and durvalumab should be evaluated under
similar parameters to the studies discussed in this paper to understand their efficacy in
prolonging overall survival in patients with NSCLC.
When the primary outcome of a study is prolonging or increasing overall survival, any
increase from the current therapy available should be evaluated further and offered to patients
with diseases who may benefit. In the upcoming years, it is expected that immunomodulating
agents will make a greater impact in treating lung metastasis due to the promising results already
seen. In a future study design, it would be adventitious to include all medications under the
programmed death pathway and compare efficacy as first and second or consecutive line therapy.
Additionally, inclusion of more study types, such as a cohort or prospective/retrospective
analyses should be included. This information could determine which medication out of the drug
class may offer the highest superiority in treating patients with advanced NSCLC whose tumors
express PD-L1
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